{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-21-134399","form_type":"8-K","ticker":"NXTC","cik":"0001661059","company_name":"NextCure, Inc.","filed_at":"2021-11-04T23:59:59+00:00","discovered_at":"2026-05-14T18:04:13.547246+00:00","generated_at":"2026-06-28T13:06:27.985304+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"NextCure Q3 2021 net loss widens to $17.9M; cash position $235.3M","bullets":["Net loss of $17.9M for Q3 2021 vs $16.4M in Q3 2020, driven by higher R&D and G&A costs.","Cash, cash equivalents and marketable securities $235.3M at Sep 30, 2021, down $48.1M from Dec 31, 2020.","R&D expenses $13.6M (up from $12.7M) and G&A $4.9M (up from $4.7M) year-over-year.","Appointed Ellen G. Feigal and Anne Borgman to Board of Directors; added three new Scientific Advisory Board members.","Cash runway expected to fund operations into second half of 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-21-134399","json":"https://secwatch.observer/filing/0001104659-21-134399.json","markdown":"https://secwatch.observer/filing/0001104659-21-134399.md","text":"https://secwatch.observer/filing/0001104659-21-134399.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1661059/000110465921134399/0001104659-21-134399-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1661059/000110465921134399/tm2131564d3_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T13:06:27.985304+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}